Plato Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Plato Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.07M	Sell	6,249 -5	-0.1%	-$1.7K	0.14%	156
2025 Q4	$2.5M	Buy	6,254 +1,348	+27%	+$597K	0.16%	130
2025 Q3	$2.22M	Buy	4,906 +793	+19%	+$323K	0.15%	142
2025 Q2	$1.34M	Sell	4,113 -546	-12%	-$151K	0.1%	211
2025 Q1	$1.27M	Sell	4,659 -888	-16%	-$228K	0.11%	212
2024 Q4	$1.31M	Buy	5,547 +845	+18%	+$222K	0.1%	225
2024 Q3	$1.29M	Buy	4,702 +1,173	+33%	+$305K	0.1%	204
2024 Q2	$858K	Sell	3,529 -980	-22%	-$155K	0.08%	225
2024 Q1	$674K	Buy	4,509 +4,346	+2,666%	+$725K	0.07%	240
2023 Q4	$31.2K	Buy	+163	New	+$27.8K	0.04%	277

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Plato Investment Management's ALNY Position: Q1 2026 in Review

Plato Investment Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.08% in Q1 2026, selling an estimated $1.7K and leaving 6,249 shares worth $2.07M. The position accounts for 0.14% of the portfolio, ranked #156.

Plato Investment Management first reported a position in ALNY in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.5M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Plato Investment Management held 6,249 shares of Alnylam Pharmaceuticals worth $2.07M as of Q1 2026.
Plato Investment Management sold 5 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.7K.
Alnylam Pharmaceuticals made up 0.14% of Plato Investment Management's portfolio in Q1 2026, its #156 holding.
Plato Investment Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Plato Investment Management's Alnylam Pharmaceuticals position peaked at $2.5M in Q4 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Plato Investment Management's 13F filing for Q1 2026, filed 5 May 2026.